Article
Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade.
Nature cancer - 1 Oct 2023
Goswami Sangeeta, Raychaudhuri Deblina, Singh Pratishtha, Natarajan Seanu Meena, Chen Yulong, Poon Candice, Hennessey Mercedes, Tannir Aminah J, Zhang Jan, Anandhan Swetha, Kerrigan Brittany Parker, Macaluso Marc D, He Zhong, Jindal Sonali, Lang Frederick F, Basu Sreyashi, Sharma Padmanee
Abstract excerpt
Glioblastoma (GBM) tumors are enriched in immune-suppressive myeloid cells and are refractory to immune checkpoint therapy (ICT). Targeting epigenetic pathways to reprogram the functional phenotype of immune-suppressive myeloid cells to overcome resistance to ICT remains unexplored. Single-cell and spatial transcriptomic analyses of human GBM tumors demonstrated high expression of an epigenetic enzyme-histone 3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.